Crinetics Pharmaceuticals Inc. (CRNX)’s Financial Results Comparing With Nabriva Therapeutics plc (NASDAQ:NBRV)

We are comparing Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) and Nabriva Therapeutics plc (NASDAQ:NBRV) on their analyst recommendations, institutional ownership, profitability, risk, dividends, earnings and valuation. They both are Biotechnology companies, competing one another.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Crinetics Pharmaceuticals Inc. 23 243.28 N/A -1.27 0.00
Nabriva Therapeutics plc 2 56.64 N/A -2.10 0.00

We can see in table 1 the earnings per share, gross revenue and valuation of Crinetics Pharmaceuticals Inc. and Nabriva Therapeutics plc.

Profitability

Table 2 represents Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) and Nabriva Therapeutics plc (NASDAQ:NBRV)’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
Crinetics Pharmaceuticals Inc. 0.00% -27% -20.8%
Nabriva Therapeutics plc 0.00% -162.3% -117.6%

Liquidity

Crinetics Pharmaceuticals Inc.’s Current Ratio is 18 while its Quick Ratio is 18. On the competitive side is, Nabriva Therapeutics plc which has a 5.6 Current Ratio and a 5.6 Quick Ratio. Crinetics Pharmaceuticals Inc. is better positioned to pay off short and long-term obligations compared to Nabriva Therapeutics plc.

Insider & Institutional Ownership

Institutional investors owned 97.6% of Crinetics Pharmaceuticals Inc. shares and 49.6% of Nabriva Therapeutics plc shares. About 5.65% of Crinetics Pharmaceuticals Inc.’s share are owned by insiders. Comparatively, insiders own roughly 0.61% of Nabriva Therapeutics plc’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Crinetics Pharmaceuticals Inc. -16.58% -18.91% -21.15% -18.03% -20.72% -32.38%
Nabriva Therapeutics plc -0.21% -1.86% 9.45% 24.35% -11.71% 62.67%

For the past year Crinetics Pharmaceuticals Inc. has -32.38% weaker performance while Nabriva Therapeutics plc has 62.67% stronger performance.

Summary

On 6 of the 7 factors Crinetics Pharmaceuticals Inc. beats Nabriva Therapeutics plc.

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly. The company is also developing CRN02481, an oral selective nonpeptide somatostatin type 5 receptor agonist used for the treatment of congenital hyperinsulinism; and CRN01941, an oral, selective nonpeptide sst2 biased agonist designed for the treatment of neuroendocrine tumors. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of novel antibiotics to treat serious bacterial infections with a focus on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, a novel semi-synthetic pleuromutilin antibiotic for systemic administration in humans. The companyÂ’s product, lefamulin is being studied in two registrational Phase 3 clinical trials in patients with moderate to severe community-acquired bacterial pneumonia. It is also developing lefamulin that has completed Phase 2 clinical trial for the treatment of acute bacterial skin and skin structure infections, as well as in preclinical studies for antibacterial activity against various gram-positive bacteria, gram-negative bacteria, and atypical bacteria, including multi-drug resistant strains. In addition, the company is developing BC-7013, a topical pleuromutilin product candidate, which has completed a Phase 1 clinical trial for the treatment of various gram-positive infections, including uncomplicated skin and skin structure infections. Nabriva Therapeutics plc was founded in 2006 and is based in Dublin, Ireland.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.